Inotek tanks after placebo beats drug in glaucoma phase 3

Nasdaq screens
Inotek pinned the failure on performance in the placebo arm.

A phase 3 glaucoma trial of Inotek Pharmaceuticals’ trabodenoson has missed its primary endpoint. The failure of the drug to beat placebo in terms of cutting intraocular pressure has thrown the future of the monotherapy program into doubt—and wiped more than 60% off Inotek’s share price in premarket trading.

Inotek compared the intraocular pressure of participants in the three treatment arms of the study to the placebo cohort at 12 time points throughout the 12-week trial. To hit the primary endpoint, trabodenoson needed to beat placebo at all 12 time points, something it failed to achieve.

The Lexington, MA-based drug developer is pinning the poor performance on lower-than-expected intraocular pressures among the placebo cohort. Specifically, when investigators took the first of each day’s readings at 8am the levels were down on those seen in the placebo cohort of the phase 2. More importantly, levels were similar to those seen in the trabodenoson arms of the phase 3.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

In its search for causes for optimism, Inotek focused in on the 6% dose cohort. This 61-subject arm bested the 62-patient placebo group against some secondary endpoints. Inotek will cling to the hope offered by those data points as it heads toward a readout on a trial of trabodenoson in combination with latanoprost.

“Looking ahead, 2017 is an important year for the trabodenoson development program. We will wait for the full results from MATrX-1 to better understand the behavior of the placebo arm. We look forward to the results of the FDC phase 2 trial, which is substantially enrolled and for which we expect to report top-line data mid-year,” Inotek CEO David Southwell said in a statement.

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.